This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

IntriCon Reports 2011 Second-Quarter Results

IntriCon Corporation (NASDAQ: IIN), a designer, developer, manufacturer and distributor of miniature and micro-miniature body-worn devices, today announced financial results for its second quarter ended June 30, 2011.

For the 2011 second quarter, the company reported net sales of $13.9 million, versus net sales of $14.9 million for the prior-year period. IntriCon reported a net loss in the 2011 second quarter of $294,000, or $0.05 per diluted share, compared to net income of $269,000, or $0.05 per diluted share, for the prior-year second quarter.

“We believe we are well positioned to serve markets with strong growth prospects long term. However, the continued economic softness has clearly applied pressure on all of our core businesses,” said Mark S. Gorder, president and chief executive officer of IntriCon. “In addition, while our steadfast approach to increasing R&D investment has led to recent design wins across all markets, it has had a short-term adverse financial impact. We anticipate top-line contributions from these design wins beginning in early 2012.

“We are pleased that hearing health revenues were up over the year-ago period. Additionally, our medical revenues increased sequentially from the first quarter. However, they were lower than historical levels as a few of our large medical customers experienced fluctuations in demand and are working through inventory levels above their immediate needs. We continue to believe this lull in medical orders is temporary, and are working very closely with our customers to monitor the situation.

“In professional audio communications, orders were impacted by delays in funding for government sponsored programs—this was particularly evident in our security business. Funding is now in place and we anticipate this portion of the business to rebound during the second half of the year.”

Second-Quarter ResultsHearing health revenue rose 7.4 percent from the 2010 second quarter as certain niches within the market continued to strengthen. Medical and professional audio communications declined 11.4 percent and 17.5 percent, respectively, from the prior-year period due to the factors noted above.

Said Gorder, “Although we are disappointed with our performance in medical and professional audio communications, the long-term fundamentals remain strong. We believe the market demand for small, lightweight advanced body-worn monitoring and communication devices is increasing, as evidenced by recent design wins. Our hearing health business continues to benefit from market acceptance of our innovative digital signal processing, or DSP, circuits, such as our new Overtus™ DSP amplifier.”

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
YHOO $27.05 -3.29%
AAPL $95.01 1.05%
FB $99.75 -4.15%
GOOG $682.74 -0.12%
TSLA $147.99 -8.99%


Chart of I:DJI
DOW 16,027.05 -177.92 -1.10%
S&P 500 1,853.44 -26.61 -1.42%
NASDAQ 4,283.7530 -79.3910 -1.82%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs